Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Félix Bonilla, Cristina Peña, Belén Pérez-Sacristán, F. Granado-Lorencio, Gemma Domínguez, Beatriz Gil-Calderón, Jesús Espinosa Romero, Encarnación Donoso, Coral San Millán, Beatriz Soldevilla, Marta Compte, Paloma Martín
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: The acquired resistance to chemotherapy represents the major limitation in the treatment of cancer. New strategies to solve this failure and improve patients' outcomes are necessary. The cancer preventive effect of β-cryptoxanthin has
Publikováno v:
Clinical Cancer Research. 21:2207-2210
Drug resistance remains a major impediment in the development of durable cancer therapies. Studies in acute myelogenous leukemia (AML) patients revealed a new form of multidrug resistance. Here, increased glioma-associated protein GLI1 leads to eleva
Autor:
Naoya Fujita, Elizabeth L. Lockerman, Yuka Kobayashi, Ryohei Katayama, Luc Friboulet, Alice T. Shaw, Sumie Koike, Jeffrey A. Engelman
Publikováno v:
Clinical Cancer Research. 21:166-174
Purpose: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non–small cell
Autor:
Sam S. Yoon, Deirdre Jill Cohen, Benjamin Schmidt, Do Joong Park, Chang Hwan Yoon, Teresa S. Kim, Yelena Y. Janjigian, Hae-June Lee, Nicholas J. Thomas
Publikováno v:
Clinical Cancer Research. 20:3974-3988
Purpose: Gastric cancers may harbor a subset of cells with cancer stem cell (CSC) properties, including chemotherapy resistance, and CD44 is a gastric CSC marker. The Hedgehog (HH) pathway is a key developmental pathway that can be subverted by CSCs
Autor:
Eileen Fung, Kostyantyn Krysan, Jay M. Lee, Manash K. Paul, W. Dean Wallace, David Elashoff, Steven M. Dubinett, Michael C. Fishbein, Jane Yanagawa, Mi-Heon Lee, Rong Guo, John D. Minna
Publikováno v:
Clinical Cancer Research. 24:B20-B20
Background: Interferon-gamma (IFN-g) is known to play a pivotal role in PD-L1 expression and immune evasion in cancer cells, but there is little known regarding its interactions with premalignant lung lesions. Methods: Immortalized human bronchial ep
Publikováno v:
Clinical Cancer Research. 18:4691-4701
Purpose: Histone deacetylase inhibitors (HDACi) are actively explored as new-generation epigenetic drugs but have low efficacy in cancer monotherapy. To reveal new mechanism for combination therapy, we show that HDACi induce cell death but simultaneo
Autor:
J. Silvio Gutkind, Alfredo A. Molinolo, Panomwat Amornphimoltham, Vyomesh Patel, Kantima Leelahavanichkul
Publikováno v:
Clinical Cancer Research. 14:8094-8101
Purpose: The activation of Akt/mammalian target of rapamycin (mTOR) pathway represents a frequent event in squamous cell carcinoma (SCC) progression, thus raising the possibility of using specific mTOR inhibitors for the treatment of SCC patients. In
Publikováno v:
Clinical Cancer Research. 12:7165-7173
Purpose: Thalidomide has been reported to have antiangiogenic and antimetastatic effects. Intercellular adhesion molecule-1 (ICAM-1) was shown to be involved in monocyte adherence to epithelial cells and cancer cell invasion. In this study, we furthe
Autor:
Paul Workman
Publikováno v:
Clinical Cancer Research. 23:IA16-IA16
It is interesting and informative to review how the ‘Hallmarks' or Phenotypic Traits of cancers became codified and evolved over time. The original and now seminal ‘Hallmarks of Cancer' article by Hanahan and Weinberg (Cell 100 646-74 2000) codif
Publikováno v:
Clinical Cancer Research. 22:A68-A68
Background: Sphingosine kinase 1 (SPHK1) is over-expressed in multiple cancers including breast and colon cancer. SPHK1 catalyzes the phosphorylation of sphingosine to sphingosine 1-phosphate (S1P). S1P promotes tumorigenesis by inhibiting apoptosis